

Retrophin

Retrophin, Inc.
Investor Relations Department
12255 El Camino Real Suite 250
San Diego, CA 92130
United States

Visit IR website [↗](#)
Sign-up for Email alerts [↗](#)

NASDAQ: RTRX

Last Trade:	20.54
Trade Time:	2:48 PM ET Jul 28, 2017
Change:	0.31 ▲ (+1.532%)
Day Range	20.12 - 20.56
52-Week Range	15.55 - 24.57
Volume	135,769

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Retrophin, Inc. (NASDAQ: RTRX) is a publicly-traded, San Diego-based biopharmaceutical company focused on the discovery, acquisition, development and commercialization of drugs for the treatment of debilitating and often life-threatening diseases for which there are currently limited patient options. The Company is currently focused on several catastrophic diseases affecting children, including Focal Segmental Glomerulosclerosis (FSGS), Pantothenate Kinase-Associated Neurodegeneration (PKAN), and others.

Retrophin is currently enrolling patients in a potentially pivotal Phase ... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

Jul 26, 2017

[Retrophin to Report Second Quarter 2017 Financial Results](#)

Jul 25, 2017

[Retrophin Commences Patient Dosing in International, Registrational Phase 3 Trial of RE-024 in PKAN](#)

Jun 1, 2017

[Retrophin Announces Expansion of Intellectual Property Estate for Sparsentan with Newly Issued Patents in the United States and Europe](#)

May 25, 2017

[Retrophin Announces Presentations for Late-Stage Clinical Development Programs at Upcoming Medical Congresses](#)

May 23, 2017

[Retrophin to Present at the Jefferies 2017 Global Healthcare Conference](#)

Financials [\[View all \]](#)

[Second Quarter Financial Results](#)

Mar 1, 2017

[Annual Report \(10-K\)](#)

Apr 14, 2017

[Proxy Statement \(DEF 14A\)](#)

May 5, 2017

[Quarterly Report \(10-Q\)](#)

Nov 4, 2016

[Quarterly Report \(10-Q\)](#)

Aug 5, 2016

[Quarterly Report \(10-Q\)](#)